Multidimensional analysis of the learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies

Annals of Surgery

Volumn 255, Issue 2, 2012, Pages 348-356

  Kusamura, Shigeki ^a   Baratti, Dario ^a   Deraco, Marcello ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; MITOMYCIN C; SERUM ALBUMIN;

ABDOMINAL ABSCESS; ABDOMINAL SURGERY; ADULT; AGED; ALBUMIN BLOOD LEVEL; ANASTOMOSIS LEAKAGE; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CARCINOMATOSIS; COLORECTAL CANCER; CYTOREDUCTIVE SURGERY; DIGESTIVE SYSTEM PERFORATION; FEMALE; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; KIDNEY FAILURE; LEARNING CURVE; LENGTH OF STAY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NEUTROPENIC INFECTION; OPERATION DURATION; OUTCOME ASSESSMENT; OVARY CANCER; PERITONEAL CARCINOMATOSIS; PERITONEAL SARCOMATOSIS; PERITONEAL SURFACE MALIGNANCY; PERITONECTOMY; PERITONEUM CANCER; PERITONEUM MESOTHELIOMA; PERITONEUM PSEUDOMYXOMA; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROBABILITY; RISK ASSESSMENT; STOMACH CANCER; SURGICAL MORTALITY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CISPLATIN; CLINICAL COMPETENCE; COMBINED MODALITY THERAPY; DIGESTIVE SYSTEM SURGICAL PROCEDURES; DOXORUBICIN; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; LEARNING CURVE; LOGISTIC MODELS; MALE; MIDDLE AGED; MITOMYCIN; ODDS RATIO; PERITONEAL NEOPLASMS; PERITONEUM; RETROSPECTIVE STUDIES; RISK ADJUSTMENT; SURGICAL PROCEDURES, OPERATIVE; TREATMENT OUTCOME;

EID: 84855830266     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3182436c28     Document Type: Article

References (37)

1. Elias D, Gilly F, Quenet F, et al. Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol. 2010;36:456-462.
2. Baratti D, Kusamura S, Nonaka D, et al. Pseudomyxoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg. 2009;249:243-249.
3. Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multiinstitutional experience. J Clin Oncol. 2009;27:6237-6242.
4. Deraco M, Baratti D, Cabras AD, et al. Experience with peritoneal mesothelioma at the Milan National Cancer Institute. World J Gastrointest Oncol. 2010;2:76-84.
5. Cao C,Yan TD, Black D, et al.Asystematic reviewandmeta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin [review]. Ann Surg Oncol. 2009;16:2152-2165.
6. Esquivel J, Elias D, Baratti D, et al. Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination [review]. J Surg Oncol. 2008;98:263-267.
7. Yan TD, Black D, Sugarbaker PH, et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer [review]. Ann Surg Oncol. 2007;14:2702-2713. (Pubitemid 47460649)
8. Raspagliesi F, Kusamura S, Campos Torres JC, et al. Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: the experience of National Cancer Institute of Milan. Eur J Surg Oncol. 2006;32:671-675. (Pubitemid 44063998)
9. Kusamura S, Younan R, Baratti D, et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer. 2006;106:1144-1153.
10. Deraco M, Baratti D, Kusamura S. Morbidity and quality of life following cytoreduction and HIPEC [review]. Cancer Treat Res. 2007;134:403-418.
11. Yan TD, Links M, Fransi S, et al. Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy-a journey to becoming a Nationally Funded Peritonectomy Center. Ann Surg Oncol. 2007;14:2270-2280. (Pubitemid 47174916)
12. Moradi BN III, Esquivel J. Learning curve in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2009;100:293-296.
13. Smeenk RM, Verwaal VJ, Zoetmulder FA. Learning curve of combinedmodality treatment in peritoneal surface disease. Br J Surg. 2007;94:1408-1414. (Pubitemid 350144391)
14. Mohamed F, Moran BJ. Morbidity and mortality with cytoreductive surgery and intraperitoneal chemotherapy: the importance of a learning curve [review]. Cancer J. 2009;5:196-199.
15. Matheny ME, Ohno-Machado L, Resnic FS. Risk-adjusted sequential probability ratio test control chart methods for monitoring operator and institutional mortality rates in interventional cardiology. Am Heart J. 2008;155:114-120. (Pubitemid 350234774)
16. Rogers CA, Reeves BC, CaputoM, et al. Control chart methods for monitoring cardiac surgical performance and their interpretation. J Thorac Cardiovasc Surg. 2004;128:811-819. (Pubitemid 39575284)
17. Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29-42.
18. Deraco M, Baratti D, Kusamura S, et al. Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies. J Surg Oncol. 2009;100:321-328.
19. Jacquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res. 1996;15:49-58. (Pubitemid 26130826)
20. Fujimoto S, Takahashi M, Kobayashi K, et al. Combined treatment of pelvic exenterative surgery and intra-operative pelvic hyperthermochemotherapy for locally advanced rectosigmoid cancer: report of a case. Surg Today. 1993;23:1094-1098. (Pubitemid 24007971)
21. Baratti D, Kusamura S, Nonaka D, et al. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2008;15:526-534.
22. Rossi CR, Foletto M, Mocellin S, et al. Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study. Cancer. 2002;94:492-499. (Pubitemid 34081381)
23. Younan R, Kusamura S, Baratti D, et al. Morbidity, toxicity, and mortality classification systems in the local regional treatment of peritoneal surface malignancy [review]. J Surg Oncol. 2008;98:253-257.
24. Younan R, Kusamura S, Baratti D, et al. Bowel complications in 203 cases of peritoneal surface malignancies treated with peritonectomy and closed-technique intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2005;12:910-918. (Pubitemid 41504224)
25. Kusamura S, Baratti D, Younan R, et al. Impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on systemic toxicity. Ann Surg Oncol. 2007;14:2550-2558. (Pubitemid 47393524)
26. Charlson ME, Pompei P,AlesKL, et al.Anewmethod of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40:373-383. (Pubitemid 17055592)
27. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29-36. (Pubitemid 12142173)
28. LemeshowS, HosmerDWJr.Areviewof goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol. 1982;115:92-106. (Pubitemid 12205725)
29. Chua T, Yan TD, Saxena A, et al. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? a systematic review of morbidity and mortality. Ann Surg. 2009;249:900-907.
30. Glehen O, Gilly FN, Boutitie F, et al. French Surgical AssociationToward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer. 2010;15:5608-5618.
31. Park IJ, Choi GS, Lim KH, et al. Multidimensional analysis of the learning curve for laparoscopic resection in rectal cancer. J Gastrointest Surg. 2009;13:275-281.
32. Steiner SH, Cook RJ, FarewellVT. Risk-adjusted monitoring of binary surgical outcomes. Med Decis Making. 2001;21:163-169. (Pubitemid 32452761)
33. Tekkis PP, Senagore AJ, Delaney CP, et al. Evaluation of the learning curve in laparoscopic colorectal surgery: comparison of right-sided and left-sided resections. Ann Surg. 2005;242:83-91. (Pubitemid 40917971)
34. Son GM, Kim JG, Lee JC, et al. Multidimensional analysis of the learning curve for laparoscopic rectal cancer surgery. J Laparoendosc Adv Surg Tech A. 2010;20:609-617.
35. Schlachta CM, Mamazza J, Seshadri PA, et al. Defining a learning curve for laparoscopic colorectal resections. Dis Colon Rect. 2001;44: 217-222. (Pubitemid 32173770)
36. Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol. 2007;18:985-990. (Pubitemid 47050488)
37. Benedix F, Reimer A, Gastinger I, et al. Study Group Colon/Rectum Carcinoma Primary Tumor. Primary appendiceal carcinoma-epidemiology, surgery and survival: results of a German multi-center study. Eur J Surg Oncol. 2010;36:763-771.